LYMPHOCYTE SUBPOPULATIONS IN GASTRIC AND COLORECTAL CANCER PATIENTS AFTER IMMUNOTHERAPY WITH ACTIVATED LYMPHOCYTES

Phenotyping of peripheral blood lymphocytes and immune activation markers of activation (HLADR, CD38, CD69, CD314, CD25) was performed in thirteen patients with disseminated forms of stomach and rectal cancer before cell treatment, and following adoptive immunotherapy with activated lymphocytes. It...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: E. V. Abakushina, Yu. V. Marizina, G. S. Neprina, I. A. Pasova, B. A. Berdov
Formato: article
Lenguaje:RU
Publicado: SPb RAACI 2014
Materias:
Acceso en línea:https://doaj.org/article/ea42dd37277a49c1904ef89e931365df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Phenotyping of peripheral blood lymphocytes and immune activation markers of activation (HLADR, CD38, CD69, CD314, CD25) was performed in thirteen patients with disseminated forms of stomach and rectal cancer before cell treatment, and following adoptive immunotherapy with activated lymphocytes. It wasshown that the lymphocytes are well activated and are able to proliferate in vitro. It was revealed that the relative content of Tregs and NK cells is increased in these patients. After the courses of immunotherapy, initially low levels of B-cells (average 5%) remained in all the patients, whereas concentration of Тregs didn’t change. Increased expression of activation markers was revealed for all lymphocyte subsets (CD25, CD314, CD38, HLA-DR) and, especially, for T-lymphocytes (CD3+HLA-DR, CD3+CD38+). Significant decrease of T helpers, activated NK-cells (CD16+CD314+) and CD4+/CD8+ was noted in peripheral blood. A non-significant elevation in mature lymphocytes (CD45RO+) and reduced content of young lymphocytes (CD45RA+) were revealed. Adoptive immunotherapy is safe and well tolerated, being characterized by lack of side effects, and it may be recommended as a complement to conventional radio- and chemotherapy.